IL‐15 Plus Thymosin α1 Reduces Senescent Hepatic CD8 + T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression
Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1600-1613
DOI: 10.1111/jgh.70359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 26.03.2026. Verfasst von Fengtian Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore B…. Hauptthemen laut MEDLINE: Interleukin-15, CD8-Positive T-Lymphocytes, Thymalfasin, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aim CD8 + T cell immunosenescence drives hepatocellular carcinoma (HCC) progression and impedes therapeutic efficacy. We hypothesized that combining interleukin‐15 (IL‐15), which rescues senescent CD8 + T cells peripherally, with thymosin alpha 1 (Tα1), which replenishes the T cell pool via thymic rejuvenation, may synergistically overcome immunosenescence and enhance antitumor immunity in HCC.
Methods
An orthotopic HCC model was established in aged C57BL/6 mice (22–26 months), randomly assigned to receive saline, IL‐15, Tα1, or combined therapy. Tumor progression was monitored by bioluminescence imaging, survival analysis, and histopathology. Hepatic CD8 + T cell phenotype and function were evaluated by multicolor flow cytometry, immunofluorescence, transcriptomic sequencing, and Western blotting. In vitro validation used primary human CD8 + T cells co‐cultured with Huh7 hepatoma cells.
Results
The combination therapy significantly suppressed tumor growth and prolonged survival. It reduced the proportion of senescent CD8 + T cells while expanding activated effector populations, enhanced proliferative capacity, and upregulated cytotoxic mediators including granzyme B, perforin, and interferon‐gamma. Transcriptomic and protein‐level analyses revealed that the combination attenuated chronically overactivated phosphatidylinositol 3‐kinase/protein kinase B signaling in hepatic CD8 + T cells. A protein kinase B agonist, SC79, abrogated these therapeutic effects in vitro, confirming pathway suppression as the key mechanism.
Conclusions
Combined IL‐15 and Tα1 therapy reverses CD8 + T cell senescence and enhances antitumor immunity in HCC through suppression of the phosphatidylinositol 3‐kinase/protein kinase B signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Developme…
- Yuhang Institute for Collaborative Innovation and Translational Research in Life Sciences and Technology, Hangzhou, China.
ORCID-Profile: Zhi Chen
Zitieren
APA
Wu, F., Guo, Z., Guan, J., Xu, J., Chen, Y., & Chen, Z. (2026). IL‐15 Plus Thymosin α1 Reduces Senescent Hepatic CD8 + T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. Journal of Gastroenterology and Hepatology, 41(5), 1600-1613. https://doi.org/10.1111/jgh.70359
Vancouver
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z. IL‐15 Plus Thymosin α1 Reduces Senescent Hepatic CD8 + T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. Journal of Gastroenterology and Hepatology. 2026;41(5):1600-1613. doi:10.1111/jgh.70359
BibTeX
@article{Wu2026,
author = {Wu, Fengtian and Guo, Zixuan and Guan, Jun and Xu, Jia and Chen, Yao and Chen, Zhi},
title = {IL‐15 Plus Thymosin α1 Reduces Senescent Hepatic CD8 + T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {5},
pages = {1600--1613},
doi = {10.1111/jgh.70359}
}
EUVIMED